NKG2D Biologic to Reduce Immune Cell Activation

A multimeric decoy to block activation of NKG2D and treat autoimmune and inflammatory diseases, and for use in vaccine development.

  • Stage: Preclinical in vivo, Preclinical in vitro
  • Type: Therapeutic, Vaccine
  • Categories: Protein / Peptide

Technology Overview

Dr. Roland Strong and Dr. Martin Prlic have developed a multimeric NKG2D decoy that will bind all NKG2D ligands and block the NKG2D pathway. NKG2D is a receptor expressed by immune cells which activates the immune cell upon ligand binding. While stimulation of NKG2D can be beneficial in some circumstances, its activation is associated with several autoimmune and inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and graft versus host disease (GVHD). NKG2D stimulation can also dampen the effectiveness of vaccine administrations. Blocking NKG2D stimulation can reduce immune cell activation as a treatment for autoimmune diseases, and for increasing vaccine efficacy.


  • Therapeutic for autoimmune and inflammatory diseases
  • Vaccine development


  • Blocks NKG2D immune response
  • Pan-NKG2D ligand masking through multiple ligand binding positions allows for lower dose with single therapeutic, in contrast with antibody-based therapeutics

Patent Information

WO 2017083545

Market Overview

Estimated that 50 million Americans have an autoimmune disease. In 2001, National Institutes of Allergy and Infectious Diseases (NIAID) estimated that annual autoimmune disease treatment costs were greater than $100 billion.

Investigator Overview

  • Roland Strong, PhD, Vaccine and Infectious Diseases Division
  • Veronika Groh-Spies, MD, Clinical Research Division
  • Thomas Spies, PhD, Clinical Research Division
  • Martin Prlic, PhD, Vaccine and Infectious Diseases Division
Tech ID: 16-006
Asset 1